Scholars Central

Review articlePublished 7 Jul 2016

Immunotherapy for Type 1 diabetes: past and future

Authors: Mona Landin-Olsson & Charlotte Erlanson-Albertsson

Diabetes Management

Volume 2 · Issue 2 · Pages 139

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Type 1 diabetes is regarded as an autoimmune disease and, in accordance with this, trials using immune suppression and general or specific immune modifications have been carried out. Most trials have been successful in animals, but it has not been possible to reproduce these results in humans. Some effects have, however, been observed in subgroups of patients, but no drug has shown a general effectiveness. The side effects have been acceptable. The failure has been suggested to be due to insufficient doses, late start or the need for a combination of drugs. It could also simply be that this is an inappropriate way to attack the disease. It is therefore time for a new approach in the battle against Type 1 diabetes. The autoimmune findings could be an expression of defense and an effort to restore damaged b cells. More effort has to be put into a critical evaluation of environmental factors to find the very early agents promoting Type 1 diabetes.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Diabetes Management.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalDiabetes Management
  • SubjectDiabetes & Endocrinology
  • BylineArticles whose byline prints “Mona Landin-Olsson & Charlotte Erlanson-Albertsson”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels